MSH|^~\&|LAB|RCH|||202002101146||ORU^R01|4164926|D|2.3|||AL|NE
PID|1||RC00007229|RC7037|LABTEST^ALMONDTHINS^||20130120|F||||||||||RC000622/19|9875495454
OBR|1|39141^LAB|00029511^1002:C00002R^LAB^100220:C2^39141|499.0000^QCOWBCHE1^QC ONE WORLD CHEMISTRY 1^^^||202002101143|202002101143|||||||202002101143||||||||||LAB|F||||
OBX|1|ST|500.1900^NA^Sodium^^2951-2^2951-2|1|130^^Y|mmol/L|135-145|L||A^S|F|||202002101147
OBX|2|ST|500.2000^K^Potassium^^2823-3^2823-3|1|3.0^^Y|mmol/L|3.5-5.0|L||A^S|F|||202002101147
OBX|3|ST|500.2100^CL^Chloride^^2075-0^2075-0|1|98^^Y|mmol/L|98-108|N||A^S|F|||202002101147
OBX|4|ST|500.2200^BICARB^Bicarbonate^^1962-0^1962-0|1|30^^Y|mmol/L|20-30|N||A^S|F|||202002101147
OBX|5|ST|500.2400^UREA^Urea^^14937-7^22664-7|1|9^^Y|mmol/L|2-9|N||A^S|F|||202002101147
OBX|6|ST|500.2600^CR^Creatinine Modified Jaffe^^14682-9^14682-9|1|< 27^^Y|umol/L|10-60|N||A^S|F|||202002101147
OBX|7|ST|500.2900^GLU^Glucose, Random^^14749-6^14749-6|1|3.6^^Y|mmol/L|3.6-7.8|N||A^S|F|||202002101147
OBX|8|ST|500.3605^LA^Lactic Acid^^2524-7^2524-7|1|1.0^^Y|mmol/L|0.5-2.2|N||A^S|F|||202002101147
OBX|9|ST|500.3800^CA^Calcium^^2000-8^2000-8|1|2.10^^Y|mmol/L|2.10-2.60|N||A^S|F|||202002101147
OBX|10|ST|500.3900^MG^Magnesium^^2601-3^2601-3|1|1.0^^Y|mmol/L|0.7-1.2|N||A^S|F|||202002101147
OBX|11|ST|500.4000^PHOS^Phosphate^^14879-1^14879-1|1|1.0^^Y|mmol/L|0.8-1.5|N||A^S|F|||202002101147
OBX|12|ST|500.4100^URIC^Uric Acid^^14933-6^14933-6|1|140^^Y|umol/L|140-360|N||A^S|F|||202002101147
OBX|13|ST|500.4500^PROT^Protein^^2885-2^2885-2|1|55^^Y|g/L|55-80|N||A^S|F|||202002101147
OBX|14|ST|500.4600^ALB^Albumin^^1751-7^61152-5|1|35^^Y|g/L|35-50|N||A^S|F|||202002101147
OBX|15|ST|500.4700^ALK^Alkaline Phosphatase^^6768-6^6768-6|1|100^^Y|U/L|100-400|N||A^S|F|||202002101147
OBX|16|ST|500.4800^GGT^Gamma Glutamyl Transferase^^2324-2^2324-2|1|156^^Y|U/L|6-16|H||A^S|F|||202002101147
OBX|17|ST|500.4900^ALT^Alanine Aminotransferase^^1742-6^1744-2|1|30^^Y|U/L|<36|N||A^S|F|||202002101147
OBX|18|ST|500.5000^AST^Aspartate Aminotransferase^^1920-8^1920-8|1|30^^Y|U/L|<36|N||A^S|F|||202002101147
OBX|19|ST|500.5200^BILT^Bilirubin, Total^^14631-6^14631-6|1|15^^Y|umol/L|2-17|N||A^S|F|||202002101147
OBX|20|ST|500.5300^BILD^Bilirubin, Direct (or Bt-Bu)^^14629-0^14629-0|1|4^^Y|umol/L|<5|N||A^S|F|||202002101147
OBX|21|ST|500.5500^LIPASE^Lipase^^3040-3^3040-3|1|40^^Y|U/L|<51|N||A^S|F|||202002101147
OBX|22|ST|500.5800^CK^Creatine Kinase^^2157-6^2157-6|1|100^^Y|U/L|<140|N||A^S|F|||202002101147
OBX|23|ST|500.6000^LD^Lactate Dehydrogenase^^14804-9^14804-9|1|150^^Y|U/L|120-300|N||A^S|F|||202002101147
OBX|24|ST|500.6755^FAST^Fasting Status^^49541-6^49541-6|1|.^^N|||N||A^S|F|||202002101147
OBX|25|ST|500.7200^OSM R^Osmolality^^2692-2^2692-2|1|280^^Y|mOsm/kg|275-295|N||A^S|F|||202002101147
OBX|26|ST|520.4300^FE^Iron^^14798-3^14798-3|1|30^^Y|umol/L|9-30|N||A^S|F|||202002101147
OBX|27|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|45^^Y|umol/L|45-70|N||A^S|F|||202002101147
OBX|28|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.67^^Y||0.15-0.55|H||A^S|F|||202002101147
NTE|1||Markedly elevated transferrin saturation.  Follow up and
NTE|2||management as per BCMA/MSP Iron Overload protocol.
OBX|29|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|5^^Y|IU/L|<10|N||A^S|F|||202002101147
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Beckman Access/DxI
OBX|30|ST|530.7340^GENTR R^Gentamicin Random^^3664-0^3664-0|1|5.0^^Y|mg/L|0.0-10.0|N||A^S|F|||202002101147
OBX|31|ST|531.3250^VANCR R^Vancomycin Random^^4091-5^4091-5|1|5.0^^Y|mg/L|0.0-40.0|N||A^S|F|||202002101147
OBX|32|ST|531.3900^DIG R^Digoxin^^14698-5^14698-5|1|2.0^^Y|nmol/L|0.6-2.6|N||A^S|F|||202002101147
NTE|1||Optimal Therap. Range for Heart Failure 0.7 - 1.3 nmol/L
NTE|2||Therap. Range for Atrial Fibrillation not well established.
NTE|3||Method:Beckman Access/DxI
OBX|33|ST|531.6110^PHNY R^Phenytoin^^14877-5^14877-5|1|80^^Y|umol/L|40-80|N||A^S|F|||202002101147
OBX|34|ST|531.7500^VALP R^Valproic Acid^^14946-8^14946-8|1|350^^Y|umol/L|350-700|N||A^S|F|||202002101147
OBX|35|ST|531.9000^CARB R^Carbamazepine^^14639-9^14639-9|1|17^^Y|umol/L|17-50|N||A^S|F|||202002101147
OBX|36|ST|532.1850^LI R^Lithium^^14334-7^14334-7|1|0.5^^Y|mmol/L|0.6-0.8|L||A^S|F|||202002101147
NTE|1||Reference refers to Maintenance Therapy Range.
NTE|2||(Acute Therapy Range is 0.8 - 1.2 mmol/L)

MSH|^~\&|LAB|RCH|||202002101147||ORU^R01|4164927|D|2.3|||AL|NE
PID|1||RC00007229|RC7037|LABTEST^ALMONDTHINS^||20130120|F||||||||||RC000622/19|9875495454
OBR|1|39141^LAB|00029511^1002:C00002R^LAB^100220:C2^39141|499.0000^QCOWBCHE1^QC ONE WORLD CHEMISTRY 1^^^||202002101143|202002101143|||||||202002101143||||||||||LAB|F||||
OBX|1|ST|500.1900^NA^Sodium^^2951-2^2951-2|1|130^^Y|mmol/L|135-145|L||A^S|F|||202002101147
OBX|2|ST|500.2000^K^Potassium^^2823-3^2823-3|1|3.0^^Y|mmol/L|3.5-5.0|L||A^S|F|||202002101147
OBX|3|ST|500.2100^CL^Chloride^^2075-0^2075-0|1|98^^Y|mmol/L|98-108|N||A^S|F|||202002101147
OBX|4|ST|500.2200^BICARB^Bicarbonate^^1962-0^1962-0|1|30^^Y|mmol/L|20-30|N||A^S|F|||202002101147
OBX|5|ST|500.2400^UREA^Urea^^14937-7^22664-7|1|9^^Y|mmol/L|2-9|N||A^S|F|||202002101147
OBX|6|ST|500.2600^CR^Creatinine Modified Jaffe^^14682-9^14682-9|1|< 27^^Y|umol/L|10-60|N||A^S|F|||202002101147
OBX|7|ST|500.2900^GLU^Glucose, Random^^14749-6^14749-6|1|3.6^^Y|mmol/L|3.6-7.8|N||A^S|F|||202002101147
OBX|8|ST|500.3605^LA^Lactic Acid^^2524-7^2524-7|1|1.0^^Y|mmol/L|0.5-2.2|N||A^S|F|||202002101147
OBX|9|ST|500.3800^CA^Calcium^^2000-8^2000-8|1|2.10^^Y|mmol/L|2.10-2.60|N||A^S|F|||202002101147
OBX|10|ST|500.3900^MG^Magnesium^^2601-3^2601-3|1|1.0^^Y|mmol/L|0.7-1.2|N||A^S|F|||202002101147
OBX|11|ST|500.4000^PHOS^Phosphate^^14879-1^14879-1|1|1.0^^Y|mmol/L|0.8-1.5|N||A^S|F|||202002101147
OBX|12|ST|500.4100^URIC^Uric Acid^^14933-6^14933-6|1|140^^Y|umol/L|140-360|N||A^S|F|||202002101147
OBX|13|ST|500.4500^PROT^Protein^^2885-2^2885-2|1|55^^Y|g/L|55-80|N||A^S|F|||202002101147
OBX|14|ST|500.4600^ALB^Albumin^^1751-7^61152-5|1|35^^Y|g/L|35-50|N||A^S|F|||202002101147
OBX|15|ST|500.4700^ALK^Alkaline Phosphatase^^6768-6^6768-6|1|100^^Y|U/L|100-400|N||A^S|F|||202002101147
OBX|16|ST|500.4800^GGT^Gamma Glutamyl Transferase^^2324-2^2324-2|1|156^^Y|U/L|6-16|H||A^S|F|||202002101147
OBX|17|ST|500.4900^ALT^Alanine Aminotransferase^^1742-6^1744-2|1|30^^Y|U/L|<36|N||A^S|F|||202002101147
OBX|18|ST|500.5000^AST^Aspartate Aminotransferase^^1920-8^1920-8|1|30^^Y|U/L|<36|N||A^S|F|||202002101147
OBX|19|ST|500.5200^BILT^Bilirubin, Total^^14631-6^14631-6|1|15^^Y|umol/L|2-17|N||A^S|F|||202002101147
OBX|20|ST|500.5300^BILD^Bilirubin, Direct (or Bt-Bu)^^14629-0^14629-0|1|4^^Y|umol/L|<5|N||A^S|F|||202002101147
OBX|21|ST|500.5500^LIPASE^Lipase^^3040-3^3040-3|1|40^^Y|U/L|<51|N||A^S|F|||202002101147
OBX|22|ST|500.5800^CK^Creatine Kinase^^2157-6^2157-6|1|100^^Y|U/L|<140|N||A^S|F|||202002101147
OBX|23|ST|500.6000^LD^Lactate Dehydrogenase^^14804-9^14804-9|1|150^^Y|U/L|120-300|N||A^S|F|||202002101147
OBX|24|ST|500.6755^FAST^Fasting Status^^49541-6^49541-6|1|.^^N|||N||A^S|F|||202002101147
OBX|25|ST|500.7200^OSM R^Osmolality^^2692-2^2692-2|1|280^^Y|mOsm/kg|275-295|N||A^S|F|||202002101147
OBX|26|ST|520.4300^FE^Iron^^14798-3^14798-3|1|30^^Y|umol/L|9-30|N||A^S|F|||202002101147
OBX|27|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|45^^Y|umol/L|45-70|N||A^S|F|||202002101147
OBX|28|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.67^^Y||0.15-0.55|H||A^S|F|||202002101147
NTE|1||Markedly elevated transferrin saturation.  Follow up and
NTE|2||management as per BCMA/MSP Iron Overload protocol.
OBX|29|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|5^^Y|IU/L|<10|N||A^S|F|||202002101147
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Beckman Access/DxI
OBX|30|ST|530.7340^GENTR R^Gentamicin Random^^3664-0^3664-0|1|5.0^^Y|mg/L|0.0-10.0|N||A^S|F|||202002101147
OBX|31|ST|531.3250^VANCR R^Vancomycin Random^^4091-5^4091-5|1|5.0^^Y|mg/L|0.0-40.0|N||A^S|F|||202002101147
OBX|32|ST|531.3900^DIG R^Digoxin^^14698-5^14698-5|1|2.0^^Y|nmol/L|0.6-2.6|N||A^S|F|||202002101147
NTE|1||Optimal Therap. Range for Heart Failure 0.7 - 1.3 nmol/L
NTE|2||Therap. Range for Atrial Fibrillation not well established.
NTE|3||Method:Beckman Access/DxI
OBX|33|ST|531.6110^PHNY R^Phenytoin^^14877-5^14877-5|1|80^^Y|umol/L|40-80|N||A^S|F|||202002101147
OBX|34|ST|531.7500^VALP R^Valproic Acid^^14946-8^14946-8|1|350^^Y|umol/L|350-700|N||A^S|F|||202002101147
OBX|35|ST|531.9000^CARB R^Carbamazepine^^14639-9^14639-9|1|17^^Y|umol/L|17-50|N||A^S|F|||202002101147
OBX|36|ST|532.1850^LI R^Lithium^^14334-7^14334-7|1|0.5^^Y|mmol/L|0.6-0.8|L||A^S|F|||202002101147
NTE|1||Reference refers to Maintenance Therapy Range.
NTE|2||(Acute Therapy Range is 0.8 - 1.2 mmol/L)